Research programme: selective estrogen receptor modulators - Forendo Pharma

Drug Profile

Research programme: selective estrogen receptor modulators - Forendo Pharma

Alternative Names: hotflushSERM™

Latest Information Update: 18 Jul 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator QuatRx Pharmaceuticals
  • Developer Forendo Pharma
  • Class
  • Mechanism of Action Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Menopausal syndrome

Most Recent Events

  • 12 Jul 2013 Forendo Pharma acquires selective estrogen receptor modulators programme from QuatRx Pharmaceuticals
  • 04 Apr 2008 Preclinical development is ongoing
  • 16 May 2005 Hormos Medical has been acquired and merged into QuatRx Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top